Zelluna is currently building a comprehensive pipeline of immunotherapeutic drug candidates based on the company's TCR portfolio.
We are developing candidates for use in adoptive cell therapy (ACT):
Our TCRs target TGFβRII, KRAS and hTERT which are widely expressed in a range of cancer types currently lacking efficient treatment. One of the TCR candidate already entered initial clinical testing under hospital exemption in 2018. First Zelluna sponsor-study with our lead TCR candidate is expected to start in 2020 and we have multiple candidates in early and late stage pre-clinical development.